Corcept's Phase 3 ROSELLA Trial Meets Overall Survival Endpoint in Platinum-Resistant Ovarian Cancer

summarizeSummary

Corcept Therapeutics announced its pivotal Phase 3 ROSELLA trial for relacorilant in platinum-resistant ovarian cancer met its overall survival primary endpoint, showing a 35% reduction in the risk of death.

check_boxKey Events

• Pivotal Phase 3 Trial Success

  The ROSELLA trial, evaluating relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer, met its overall survival primary endpoint.

• Significant Survival Benefit

  Patients treated with relacorilant experienced a 35% reduction in the risk of death (hazard ratio: 0.65; p-value: 0.0004), with a median overall survival of 16.0 months compared to 11.9 months for the control arm.

• Dual Primary Endpoints Met

  This success follows the earlier achievement of the progression-free survival primary endpoint, demonstrating a 30% reduction in disease progression risk.

• Favorable Safety Profile and Broad Applicability

  The combination therapy was well-tolerated, with adverse events comparable to nab-paclitaxel monotherapy, and the benefit was observed without the need for biomarker selection.

auto_awesomeAnalysis

This is a critical positive development for Corcept Therapeutics, as meeting the overall survival primary endpoint in a pivotal Phase 3 trial significantly de-risks the approval and commercialization of relacorilant for platinum-resistant ovarian cancer. The statistically significant and clinically meaningful improvement in overall survival, coupled with a favorable safety profile and no biomarker requirement, positions relacorilant as a potential new standard of care. With NDA and MAA applications already under review, this data strongly supports regulatory approval and future revenue growth. Investors should monitor the upcoming PDUFA date and further clinical presentations.